As GM-CSF signature correlates with both poor patient prognosis and the NrasG12D/PtenKO-specific transcriptome, we advance the potential of GM-CSF neutralization as a distinctive myeloid cell centric immunomodulation strategy in HCC, which can be further enhanced in combination with VEGF blockade standard of care. Here, CSF2 is linked to hepatocellular carcinoma.